Canaccord lowered the firm’s price target on Intra-Cellular to $100 from $101 and keeps a Buy rating on the shares. The firm said they view the shares as undervalued on Calyta’s approved indications alone and believe the company’s relatively-large ex- lumateperone pipeline is underappreciated and not in the stock in any meaningful way.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
- Intra-Cellular Therapies Business and Clinical Progress Update
- Notable companies reporting before tomorrow’s open
- Intra-Cellular price target raised to $82 from $76 at Mizuho
- Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
